JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by JPMorgan Chase & Co. from $950.00 to $1,050.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 13.16% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Raymond James Financial upped their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Finally, Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $872.00.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $927.89 on Friday. Regeneron Pharmaceuticals has a 12-month low of $591.52 and a 12-month high of $935.35. The company has a current ratio of 4.06, a quick ratio of 3.66 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average price is $793.30 and its 200-day moving average price is $738.05. The stock has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm’s revenue was up 36.3% on a year-over-year basis. During the same period in the prior year, the company earned $11.83 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 over the last ninety days. 6.97% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in REGN. Orbimed Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter worth about $11,358,000. BlackRock Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. Contravisory Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $6,327,000. Oxbow Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $3,342,000. Finally, Deutsche Bank AG purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $323,249,000. Institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.